Lantheus Holdings, Inc. LNTH

LNTH Company Overview

Lantheus Holdings, Inc. is a U.S.-based radiopharmaceutical company focused on diagnostic imaging agents, targeted radiotherapeutics, and artificial intelligence-enabled imaging solutions. The company operates primarily in the healthcare, nuclear medicine, and precision oncology industries, developing products used by hospitals, imaging centers, and physician practices for disease detection, characterization, and treatment planning. Its core revenue drivers include radiodiagnostic products used in cardiology and oncology imaging, most notably the positron emission tomography (PET) imaging agent PYLARIFY for prostate cancer imaging and DEFINITY for ultrasound enhancement. Lantheus also generates revenue through strategic collaborations, licensing arrangements, and manufacturing services related to radiopharmaceutical technologies.

Founded in 1956 as part of New England Nuclear and later operating under Bristol-Myers Squibb before becoming an independent company, Lantheus evolved from a traditional diagnostic imaging supplier into a precision medicine and radiopharmaceutical platform company. The company has increasingly emphasized oncology-focused imaging and theranostics, leveraging its manufacturing and distribution infrastructure in nuclear medicine. Its strategic positioning is supported by an established commercial network in radiopharmaceutical distribution, specialized production capabilities, and relationships with imaging providers across the United States and selected international markets.